Oligonucleotide News and Research

RSS

Study: Anti-microRNA drug significantly reduces miR-92a levels in human peripheral blood

A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.

12 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

Researchers develop new therapeutic approach to treat CLN3 Batten disease

Researchers led by a team at Rosalind Franklin University of Medicine and Science have devised a new therapeutic approach to treating a rare but deadly neurodegenerative genetic disease in children.

31 Jul 2020

Neurotransmitter-derived lipidoids help carry drugs across the blood-brain barrier in mice

Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even gene editing proteins across the blood-brain barrier and into the brain in mice.

24 Jul 2020

Study: L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer

The cover for issue 29 of Oncotarget features, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.

23 Jul 2020

Experimental drug for rare ALS shows promise in early clinical trial

An experimental drug for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a phase 1/phase 2 clinical trial conducted at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston and other sites around the world and sponsored by the pharmaceutical company Biogen Inc.

8 Jul 2020

Developing Vaccines and Therapeutics by Exploiting Structure in Spherical Nucleic Acids

An interview discussing the use of spherical nucleic acids (SNAs) and what they show about the importance of structure in pharmaceutical development.

From Pittcon 2 Jul 2020

Structure of the full SARS-CoV-2 RNA genome in infected cells

The current COVID-19 pandemic caused by a single-stranded RNA virus, thought to have jumped across species barriers to infect humans, has spread rapidly across the globe infecting over 10 million individuals. The virus, now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of COVID-19 disease. COVID-19 disease is a respiratory illness where symptoms can range from very mild to severe and include fever, coughing, a sore throat, and shortness of breath.

2 Jul 2020

Researchers develop a potential treatment approach for Pelizaeus-Merzbacher disease

A team led by Case Western Reserve University medical researchers has developed a potential treatment method for Pelizaeus-Merzbacher disease (PMD), a fatal neurological disorder that produces severe movement, motor and cognitive dysfunction in children.

1 Jul 2020

Researchers develop potential new therapy for common form of muscular dystrophy

Researchers have designed a potential new treatment for one of the most common forms of muscular dystrophy, according to a new study published today in the Proceedings of the National Academy of Sciences.

29 Jun 2020

Parkinson's disease breakthrough seen in mouse model

Researchers from the University of California San Diego School of Medicine have found a way to create new neurons in a mouse model of Parkinson's disease. The severely debilitating and progressive neurodegenerative disease, as of now, has no cure, and this breakthrough could help hundreds of thousands of patients with the condition feel experts.

25 Jun 2020

New therapeutic approach for Parkinson’s and other neurodegenerative diseases

Xiang-Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied the basic biology of RNA, a genetic cousin of DNA, and the proteins that bind it. But a single discovery has launched Fu into a completely new field: neuroscience.

25 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020

Mapping RNA sequences of therapeutic value in the SARS-CoV-2 genome

Now, in new research published on the preprint server bioRxiv European scientists have performed RNA structure probing to obtain a single-base resolution secondary structure map of the full SARS-CoV-2 coronavirus genome.

17 Jun 2020

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies, today announced that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington's Disease were published in the peer-reviewed journal Neurobiology of Disease.

3 Jun 2020

New Thermo Scientific Proteome Discoverer 2.5 software strengthens laboratory workflows

Scientists in the life sciences can now benefit from upgrades to a suite of analytical software solutions with new features designed to enhance productivity, confidence and accuracy in numerous fields, including proteomics, food safety and biotherapeutic drug development.

From Thermo Fisher Scientific Inc. 28 May 2020